Shares of Charles River Laboratories (NYSE:CRL) are off 14% year to date as of Sept. 18, and some hedge funds are buying the dip. However, others have given up, dumping their shares during the first or second quarters.
Upslope Capital Management initiated a new position in Charles River Laboratories during Q4 2024 - only to turn around and exit in the next quarter. Meanwhile, Oakmark established a position in the stock during Q2 2025.
Also see: Hedge Funds Are Pouring Into This Stock As One Manager Exits, Citing “Cracks”
Will Charles River recover, or is it destined to remain in the doldrums for the long term?
Background on Charles River Laboratories
Charles River is a contract research organization (CRO) that supports pharmaceutical and biotech companies in bringing products to the market. The company’s services are aimed at accelerating drug development, starting at the very earliest stages involving basic research and discovery of new drugs.
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
